289 related articles for article (PubMed ID: 38489062)
21. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
22. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
[TBL] [Abstract][Full Text] [Related]
23. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
24. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
[TBL] [Abstract][Full Text] [Related]
25. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
[TBL] [Abstract][Full Text] [Related]
26. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
27. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
28. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
Akenroye AT; Heyward J; Keet C; Alexander GC
J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
[TBL] [Abstract][Full Text] [Related]
29. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
Pérez de Llano LA; Cosío BG; Domingo C; Urrutia I; Bobolea I; Valero A; Entrenas Costa LM; Quirce S; Barranco P; Marina Malanda N; Andrés LP; Alvarez-Gutiérrez FJ
J Allergy Clin Immunol Pract; 2019; 7(7):2277-2283.e2. PubMed ID: 30677539
[TBL] [Abstract][Full Text] [Related]
31. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
32. A drug safety review of treating eosinophilic asthma with monoclonal antibodies.
Mitchell P; Leigh R
Expert Opin Drug Saf; 2019 Dec; 18(12):1161-1170. PubMed ID: 31594389
[No Abstract] [Full Text] [Related]
33. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
34. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase
Dernoncourt A; Liabeuf S; Bennis Y; Masmoudi K; Bodeau S; Laville S; Hurtel-Lemaire AS; Gras-Champel V; Batteux B
BioDrugs; 2023 Jan; 37(1):73-87. PubMed ID: 36401769
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
36. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
[TBL] [Abstract][Full Text] [Related]
37. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
38. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of refractory asthma with antibodies].
Lommatzsch M
Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
[TBL] [Abstract][Full Text] [Related]
40. Safety of biological therapy in elderly patients with severe asthma.
Mir-Ihara P; Narváez-Fernández E; Domínguez-Ortega J; Entrala A; Barranco P; Luna-Porta JA; Romero D; Villamañán E; Losantos-García I; Quirce S
J Asthma; 2022 Nov; 59(11):2218-2222. PubMed ID: 34889165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]